We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma

News   Sep 01, 2011

 
MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma
 
 
 

RELATED ARTICLES

Natural Plant Defense Genes

News

In a new study, researchers identify genes and metabolic pathways responsible for safener efficacy in grain sorghum.

READ MORE

A New Perspective on Immune and Blood Cell Production

News

Tracking and quantifying the production of different kinds of blood cells and immune cells has provided new insights on how the body maintains a balanced supply.

READ MORE

Drug Designed to Treat Opioid Cravings Begins Clinical Trial Testing

News

Researchers at the University of Maryland School of Medicine (UMSOM) Institute of Human Virology (IHV) are collaborating with scientists at the National Institutes of Health to test an experimental drug to curb opioid cravings.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE